Emerging Template Market Growth Trends: How Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics is Reshaping Market Size & Industry Expansion

 The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.

 
 #How have key drivers contributed to the rapid growth of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?
 The increasing number of people with diabetes is expected to propel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market going forward. Diabetes refers to a chronic metabolic disorder characterized by high blood sugar levels (hyperglycemia) over a prolonged period. This condition results from the body’s inability to produce enough insulin or effectively use the insulin it produces. EPI therapy, which involves pancreatic enzyme replacement therapy (PERT), can help improve nutrient absorption in people with diabetes and EPI. It can also help improve glycemic control in people with diabetes. For instance, in June 2024, according to The National Health Service (NHS England), a UK-based publicly funded healthcare system, in 2023, the number of individuals identified by the NHS in England as having pre-diabetes rose to 3,615,330, marking an 18% increase from 3,065,825 in 2022. Additionally, among those under 40, cases surged nearly 25%, growing from 173,166 in 2022 to 216,440 in 2023. Therefore, the increasing number of people with diabetes is driving the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
 
 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Driver: Growing Incidence Of Gastrointestinal Disorders Is Anticipated To Drive Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics
 
 The increasing incidence of gastrointestinal diseases is expected to propel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market going forward. Gastrointestinal diseases refer to a group of medical conditions that affect the gastrointestinal tract, which includes the organs responsible for digestion. Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics play a crucial role in managing gastrointestinal diseases by addressing the underlying enzyme deficiency and aiding in the proper digestion of nutrients. Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics play a crucial role in the management of gastrointestinal diseases, as they address the underlying enzyme deficiency and assist in digestion. For instance, in June 2023, according to Crohn’s and Colitis Canada, a Canada-based non-profit organization, over 322,600 Canadians were estimated to be living with inflammatory bowel diseases (IBD) in 2023, accounting for approximately 0.82% of the population. As the prevalence of IBD continues, it is estimated that around 470,000 Canadians will be living with IBD by 2035, approximately 1.1% of the population, or 1 in every 91 people in the country. Therefore, the increasing incidence of gastrointestinal diseases is expected to propel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
 
 #Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report — Get Insights Now!#
 https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
 
 #How has the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size evolved, and what are the latest forecasts for its expansion?#
 The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size has grown strongly in recent years. It will grow from $5.69 billion in 2024 to $6.17 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, rising global healthcare access.
 
 The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $8.32 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.
 
 #Gain Exclusive Market Insights — Customize Your Research Report Today For Fast Delivery!#
 https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp
 
 #Which major companies dominate the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?#
 Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
 
 #What trends will shape the future of the exocrine pancreatic insufficiency market?#
 Major companies operating in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are adopting a strategic partnership approach to enhance technology integration and expand market reach. A strategic partnership typically refers to a collaborative relationship between two or more organizations where they combine their resources, expertise, and efforts to achieve common goals or objectives. For instance, in February 2023, Codexis, Inc., a US-based protein engineering company, and Nestlé Health Science, a Switzerland-based science of nutrition, announced interim results from their Phase 1 clinical trial of CDX-7108, an investigational therapy aimed at treating exocrine pancreatic insufficiency (EPI). The results from this Phase 1 trial pave the way for further studies that could significantly improve treatment options for patients suffering from EPI.
 
 #Which region dominates the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market, and what factors contribute to its leadership?#
 North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 #Order Your Report Now For Swift Delivery#
 https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report
 
 #How is the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market segmented, and which segment holds the largest share?#
 The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented –
 
 1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
 2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
 3) By Drug Type: Generic, Branded
 4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
 5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
 
 Subsegments:
 1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
 2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
 3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
 
 #Purchase The Exclusive Report Now To Unlock Valuable Market Insights:#
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992
 
 #What defines the structure and scope of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?#
 Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics refer to treating a condition in which the pancreas does not produce enough digestive enzymes required for the proper breakdown and absorption of nutrients from food in the small intestine. EPI diagnostics and therapeutics play a crucial role in diagnosing and managing exocrine pancreatic insufficiency, helping individuals with EPI achieve better nutrient absorption and overall well-being.
 
 #About The Business Research Company:#
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 #Contact Us:#
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708
 
 Asia: +91 88972 63534
 
 Americas: +1 315 623 0293
 
 Email: info@tbrc.info
 
 
 #Follow Us On:#
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company